New Clinical Studies Demonstrate the Accuracy of Masimo Noninvasive and Continuous Hemoglobin Monitoring ...( http://www.asaabstracts.com/strands/asa...),Health

Date:10/21/2009

="http://www.asaabstracts.com/strands/asaabstracts/search.htm;jsessionid=6AA97B9BE07C8E5692FCA0837F4E4A47">study (A1294) comparing hemoglobin measurements in 107 subjects from time-matched arterial and venous blood samples on the same invasive laboratory device found average differences as high as 0.5 g/dL and noted that "arterial and venous hemoglobin values from the same individual are not interchangeable."(4)

Influence of Site of Measurement to Predict Automatically and Noninvasively Fluid Responsiveness (A477)(5), a clinical study led by Dr. Olivier Desebbe at the Hospices Civils de Lyon in Lyon, France, studied the finger, forehead, and ear as measurement sites for PVI and found that all three sites allowed discrimination between fluid responders and non-responders. Researchers measured hemodynamic data in 12 patients under general anesthesia using pulmonary artery catheter and Masimo PVI (obtained via noninvasive sensors attached to the forehead using a Masimo TF-I, ear using a Masimo TC-I, and finger using a Masimo LNOP Adt) before and after volume expansion of 500 ml of hetastarch 6%. Fluid responders were defined as patients presenting >15% increase in cardiac index (CI) following VE. Study results showed that a PVI >17% for the forehead and ear, and a PVI >13% for the finger before volume expansion "allowed discrimination between responders and non-responders with a sensitivity and specificity of 100 and 83% for the forehead, 83 and 100% for the ear, and 100 and 67% for the finger"--demonstrating that PVI is an accurate and reliable automatic noninvasive indicator of a patient's ability to respond to fluid and that clinicians should take site measurement into account when utilizing PVI to predict fluid responsivenes
'/>"/>

SOURCE Masimo Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results